| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | 0.029 | 0.9 |
| mRNA | 16-beta-bromoandrosterone | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | Tamoxifen | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | PF-573228 | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | Ispinesib Mesylate | GDSC1000 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | 0.0032 | 0.9 |